Revenue for the first quarter of FY2027 was JPY 4,284 million, a 7.2% increase YoY. Net income was JPY 200 million, a 108.3% increase YoY. Although revenue increased, operating profit declined due to rising costs. The full-year earnings forecast is currently undecided.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4531","jir_company_name":"Organic Synthesis Pharmaceutical Industries Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-07-31","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4531-20260731-02.pdf","jir_short_summary":"Revenue for the first quarter of FY2027 was JPY 4,284 million, a 7.2% increase YoY. Net income was JPY 200 million, a 108.3% increase YoY. Although revenue increased, operating profit declined due to rising costs. The full-year earnings forecast is currently undecided.","jir_summary":"### Financial Performance Overview\nOrganic Synthesis Pharmaceutical Industries reported revenue of JPY 4,284 million for the first quarter of FY2027, marking a 7.2% increase compared to the same period last year. Operating profit decreased sharply by 69.4%, amounting to JPY 41 million, primarily due to rising costs. Net income rose by 108.3% to JPY 200 million, driven by increased sales and improved cost management. The revenue growth is mainly attributed to strong performance in the chemical products segment.\n\n### Future Outlook and Investor Implications\nWhile the full-year earnings forecast remains undecided, the increases in revenue and net income are positive indicators. Attention should be paid to rising costs and market environment changes; however, prospects for long-term growth through expansion in the chemical segment and continued cost control remain promising. Investors should monitor upcoming performance trends and cost management strategies.","jir_financial_highlights":"Revenue: JPY 4,284 million (YoY+7.2%)\nNet Income: JPY 200 million (YoY+108.3%)\nOperating Income: JPY 41 million (YoY-69.4%)","jir_category":"","jir_hashtags":"#OrganicSynthesisPharmaceutical, #FinancialSummary, #JapanStocks","jir_key_figures":"Revenue: JPY 4,284 million (YoY+7.2%)\nNet income: JPY 200 million (YoY+108.3%)\nOperating income: JPY 41 million (YoY-69.4%)","jir_meta_title":"\u3010Organic Synthesis Pharmaceutical Industries\u3011FY2027 Q1 Financial Results \u2014 Revenue Growth and Strong Net Income","jir_meta_description":"Organic Synthesis Pharmaceutical Industries' Q1 FY2027 reports revenue of JPY 4,284 million and net income of JPY 200 million. Analyzing the drivers behind revenue growth and profit improvement, along with outlook prospects.","jir_og_title":"\u3010Organic Synthesis Pharmaceutical Industries\u3011FY2027 Financial Results \u2014 Revenue Growth & Net Income Improvement","jir_og_description":"Overview of Organic Synthesis Pharmaceutical Industries' FY2027 Q1 results and future outlook. Highlights of revenue growth and net income enhancement.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trends\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-04\\\",\\\"2026-07\\\",\\\"2026-10\\\",\\\"2027-01\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[3995,4284,\u4e0d\u660e,\u4e0d\u660e],\\\"borderColor\\\":\\\"#36A2EB\\\",\\\"fill\\\":false}]}}\"}, {\"jir_chart_id\": \"profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Trends\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-04\\\",\\\"2026-07\\\",\\\"2026-10\\\",\\\"2027-01\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[749,200,\u4e0d\u660e,\u4e0d\u660e],\\\"borderColor\\\":\\\"#4BC0C0\\\",\\\"fill\\\":false}]}}\"}, {\"jir_chart_id\": \"operating_profit\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Income\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-04\\\",\\\"2026-07\\\",\\\"2026-10\\\",\\\"2027-01\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[\u4e0d\u660e,41,\u4e0d\u660e,\u4e0d\u660e],\\\"backgroundColor\\\":\\\"#FF6384\\\"}]}}\"}]","ir_related_company":59377,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-91761","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n